Taipei Exchange - Delayed Quote TWD

BIONET TX Corp (7808.TWO)

43.50
-0.60
(-1.36%)
At close: June 13 at 10:38:15 AM GMT+8
Loading Chart for 7808.TWO
  • Previous Close 44.10
  • Open 43.20
  • Bid 42.30 x --
  • Ask 43.70 x --
  • Day's Range 43.00 - 43.50
  • 52 Week Range 37.70 - 72.60
  • Volume 7,000
  • Avg. Volume 47,121
  • Market Cap (intraday) 3.045B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.50
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

BIONET Therapeutics Corp., a biopharmaceutical company, develops cell therapy products and drug development for acute and severe diseases. The company develops treatment for adult respiratory distress syndrome, pulmonary fibrosis, chronic kidney failure, acute wound healing, chronic wound healing of diabetic ulcers, osteoarthritis, and dry eye syndrome. It also provides CRDMO services. The company was founded in 2022 and is based in Taipei, Taiwan.

www.bionettx.com

73

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 7808.TWO

View More

Performance Overview: 7808.TWO

Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

7808.TWO
6.65%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
4.18%

1-Year Return

7808.TWO
29.84%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
1.07%

3-Year Return

7808.TWO
29.84%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
37.35%

5-Year Return

7808.TWO
29.84%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
93.12%

Compare To: 7808.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 7808.TWO

View More

Valuation Measures

Annual
As of 6/13/2025
  • Market Cap

    3.04B

  • Enterprise Value

    1.83B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    30.72

  • Price/Book (mrq)

    2.35

  • Enterprise Value/Revenue

    22.51

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -106.07%

  • Return on Assets (ttm)

    -6.57%

  • Return on Equity (ttm)

    -9.46%

  • Revenue (ttm)

    81.32M

  • Net Income Avi to Common (ttm)

    -86.26M

  • Diluted EPS (ttm)

    -1.50

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.21B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -116.82M

Research Analysis: 7808.TWO

View More

Company Insights: 7808.TWO

Research Reports: 7808.TWO

View More